Archive for July, 2009
STATEMENT BY FUAD EL-HIBRI, EMERGENT BIOSOLUTIONS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ON THE PASSING OF ADMIRAL WILLIAM CROWE, JR., FORMER BOARD MEMBER.
ROCKVILLE, MD, October 19, 2007— Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, issued the following statement on the passing of Admiral William Crowe, Jr., who served on the company’s Board of Directors from 1998-2005.
“I was deeply saddened to learn of the passing of my dear friend and former colleague, the honorable Admiral [...]
July 15, 2009
Tags: Anthrax vaccines, Board of Directors, Chief executive officer, Emergent BioSolutions, Health, Infectious disease, United States., US Food and Drug Administration. Posted in: Uncategorized 
No Comments
Fuad El-Hibri Profiles
Fuad El-Hibri on backtype
Fuad El-Hibri on BigContact
Fuad El-Hibri on BlogCatalog
Fuad El-Hibri on Blogger
Fuad El-Hibri on BloggersUnite
Fuad El-Hibri on Carbonmade
Fuad El-Hibri on Disqus
Fuad El-Hibri on FriendFeed
Fuad El-Hibri on HelloTxt
Fuad El-Hibri on Identica
Fuad El-Hibri on isfingawesome
Fuad El-Hibri on koornk
Fuad El-Hibri on kwippy
Fuad El-Hibri on [...]
July 15, 2009
Tags: fuad, fuad el-hibri, fuad el-hibri profiles Posted in: Uncategorized No Comments
Emergent Biosolutions Announces That Biothrax (Anthrax Vaccine Adsorbed) Receives Market Authorization In India
Biological E. of Hyderabad, India to serve as marketing agent for BioThrax in India
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Drugs Controller General of India (DCGI) has issued a registration certificate for BioThrax® (Anthrax Vaccine Adsorbed), which enables the marketing and sale of the vaccine in India to help prevent anthrax infection. Emergent [...]
July 13, 2009
Tags: Bacillus anthracis, Biothrax, Emergent BioSolutions, Form 10-Q, Government of India, India, Private Securities Litigation Reform Act, United States., US Food and Drug Administration. Posted in: Uncategorized No Comments
U.S. Government To Purchase Additional 14.5 Million Doses Of Biothrax® Under New Contract Valued At Up To $404 Million
New contract extends USG’s commitment to purchase BioThrax through 3Q 2011 and is a follow-on to the existing 2007, $448 million contract
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and Human Services (HHS) to supply an additional 14.5 million [...]
July 13, 2009
Tags: Anthrax, Anthrax vaccines, Emergent BioSolutions, Private Securities Litigation Reform Act, Strategic National Stockpile, U.S. Food and Drug Administration, U.S. Government, United States Department of Health and Human Services, United States. Posted in: Uncategorized No Comments
Emergent Biosolutions Acquires Monoclonal Anthrax Product Candidate
Acquisition represents important addition to company’s portfolio of anthrax countermeasures
Emergent BioSolutions Inc. (NYSE: EBS) announced that today it completed the acquisition of a group of anthrax monoclonal antibodies from AVANIR Pharmaceuticals (NASDAQ:AVNR), including Avanir’s lead product candidate, AVP-21D9.
AVP-21D9 is a human monoclonal antibody product candidate that is being developed as an intravenous treatment for patients [...]
July 13, 2009
Tags: Anthrax, Clinical trial, Infectious disease, Monoclonal antibodies, National Institute of Allergy and Infectious Diseases, NIAID, U.S. Food and Drug Administration, United States. Posted in: Uncategorized No Comments
Emergent Biosolutions Submits Proposal In Response To Hhs’ Rfp For Development And Procurement Of A Recombinant Protective Antigen Anthrax Vaccine
The company’s submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and [...]
July 13, 2009
Tags: Clinical trial, Infectious disease, rPA 102, Strategic National Stockpile, U.S. Food and Drug Administration, U.S. Government, United States Department of Health and Human Services, United States., US government Posted in: Uncategorized No Comments
Emergent Biosolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate And Technology
Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product [...]
July 13, 2009
Tags: Clinical trial, Fort Detrick, Strategic National Stockpile, U.S. Food and Drug Administration, United States Department of Health and Human Services, United States., US government, VaxGen. Posted in: Uncategorized No Comments
Emergent Biosolutions Appoints Dr. W. James Jackson As Chief Scientific Officer
Emergent BioSolutions Inc. (NYSE: EBS) announced today that W. James Jackson, Ph.D., has been appointed chief scientific officer, effective immediately. Dr. Jackson will report directly to Fuad El-Hibri, chairman and chief executive officer.
As CSO, Dr. Jackson will lead the company’s scientific evaluation of new products and technology platforms and will be responsible for building and [...]
July 13, 2009
Tags: Anthrax vaccines, Biotechnology and Pharmaceuticals, Business, Chief executive officer, Infectious disease, Pharmaceutical, Research and development, U.S. Food and Drug Administration, University of Georgia. Posted in: Uncategorized No Comments
Emergent Biosolutions And Ninebio Sdn. Bhd. Announce Joint Venture In Malaysia
Newly formed company to focus on creating critical R&D and manufacturing infrastructure and supplying biodefense countermeasures within Asia and other territories.
January 24, 2008 – Emergent BioSolutions (NYSE: EBS) and Ninebio Sdn. Bhd. (“9Bio”) today announced the formation of a joint venture in Malaysia that will focus on creating critical biologics infrastructure and supplying biodefense countermeasures, [...]
July 13, 2009
Tags: Business, Chief executive officer, Emergent BioSolutions, MALAYSIA, National Institutes of Health, Private Securities Litigation Reform Act, Research and development, SEC, U.S. Food and Drug Administration, United States. Posted in: Uncategorized No Comments
About Fuad El-Hibri
Professional Background
Mr. Fuad El-Hibri is the Chairman and Chief Executive Officer of Emergent BioSolutions Inc. (Emergent), a publicly traded biopharmaceutical company focused on developing, manufacturing and commercializing vaccines and therapeutics to prevent and treat life-threatening diseases. The company’s current marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only FDA-licensed vaccine for pre-exposure prophylaxis of anthrax [...]
July 6, 2009
Posted in: Uncategorized No Comments